Delving into the Latest Updates on REGN-13335 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

REGN 13335, REGN13335

Target

PDGFB

Action

inhibitors

Mechanism

PDGFB inhibitors(Platelet-derived growth factor subunit B inhibitors)

Therapeutic Areas

Respiratory DiseasesOther DiseasesCardiovascular Diseases+ [1]

Active Indication

Pulmonary Arterial HypertensionCardiovascular DiseasesMetabolic Diseases

Inactive Indication-

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Regeneron Pharmaceuticals, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines.
The study is looking at several other research questions, including:
* What side effects may happen from taking REGN13335
* How much REGN13335 is in the blood at different times
* Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Start Date06 May 2026

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT06137482

/ CompletedPhase 1

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN13335, a Platelet-Derived Growth Factor-B Antagonist, in Healthy Adult Participants

This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.
The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is present in the blood of study participants at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Start Date06 Dec 2023

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with REGN-13335

Login to view more data

100 Translational Medicine associated with REGN-13335

Login to view more data

100 Patents (Medical) associated with REGN-13335

Login to view more data

100 Deals associated with REGN-13335

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Arterial Hypertension	Phase 2	United States	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Australia	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Belgium	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	France	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Germany	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Latvia	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Poland	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	South Korea	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	Spain	Regeneron Pharmaceuticals, Inc.	06 May 2026
Pulmonary Arterial Hypertension	Phase 2	United Kingdom	Regeneron Pharmaceuticals, Inc.	06 May 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data